We are live on ! Find out more
RDHL

Redhill Biopharma

31 hedge funds and large institutions have $18M invested in Redhill Biopharma in 2017 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

35% more funds holding

Funds holding: 2331 (+8)

0% more ownership

Funds ownership: 0%0% (+0%)

7% less capital invested

Capital invested by funds: $19.5M → $18M (-$1.43M)

75% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 8

Holders
31
Holders Change
+8
Holders Change %
+34.78%
% of All Funds
0.7%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
14
Increased
2
Reduced
8
Closed
6
Calls
Puts
Net Calls
Net Calls Change

RDHL Hedge Fund Activity: Q4 2017 in Review

31 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q4 2017, worth a combined $18M — down 7.3% from $19.5M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new RDHL positions and 6 closed out — a net gain of 8 holders — while 2 added to existing stakes and 8 trimmed.

The largest buyer was 683 Capital Management, opening a new position worth an estimated $6.73M. The largest seller was Bank Hapoalim BM, exiting entirely with an estimated $1.47M sold.

  • 31 institutional investors held Redhill Biopharma (RDHL) as of Q4 2017, up from 23 in Q3 2017.
  • Funds reported $18M of Redhill Biopharma stock for Q4 2017, down 7.3% quarter-over-quarter.
  • 14 funds opened new Redhill Biopharma positions in Q4 2017 and 6 closed out, a net change of +8 holders.
  • The largest Redhill Biopharma buyer in Q4 2017 was 683 Capital Management, an estimated $6.73M added.
  • The largest Redhill Biopharma seller in Q4 2017 was Bank Hapoalim BM, an estimated $1.47M sold.

Based on aggregated 13F filings for Q4 2017.